Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Engert

Showing results (341-350 of 379) with videos related to

Pageof 38
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2018
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 TrialPhilippe Armand, Andreas Engert, Anas Younes, et al.
JAMA Oncology|May 1, 2020
Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL TrialPaul J Bröckelmann, Helen Goergen, Ulrich Keller, et al.
Blood|September 2, 2008
Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphomaCarsten Kobe, Markus Dietlein, Jeremy Franklin, et al.
Hepatology (Baltimore, Md.)|April 5, 2012
Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventionsAndreas E Kremer, Remco van Dijk, Pamela Leckie, et al.
Leukemia|June 11, 2021
Gene expression-based outcome prediction in advanced stage classical Hodgkin lymphoma treated with BEACOPPRon D Jachimowicz, Wolfram Klapper, Gunther Glehr, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2012
Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trialsKarolin Behringer, Horst Mueller, Helen Goergen, et al.
British Journal of Haematology|August 28, 2015
Impact of centralized diagnostic review on quality of initial staging in Hodgkin lymphoma: experience of the German Hodgkin Study GroupPaul J Bröckelmann, Helen Goergen, Michael Fuchs, et al.
American Journal of Hematology|May 26, 2016
Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaborationChan Y Cheah, Paul J Bröckelmann, Dai Chihara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2010
Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trialHans Theodor Eich, Volker Diehl, Helen Görgen, et al.
Blood|December 18, 2010
Testing G-CSF responsiveness predicts the individual susceptibility to infection and consecutive treatment in recipients of high-dose chemotherapyChristian Straka, Michael Sandherr, Hans Salwender, et al.
Pageof 38

Showing results (341-350 of 379) with videos related to

Sort By:
Pageof 38
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2018
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 TrialPhilippe Armand, Andreas Engert, Anas Younes, et al.
JAMA Oncology|May 1, 2020
Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL TrialPaul J Bröckelmann, Helen Goergen, Ulrich Keller, et al.
Blood|September 2, 2008
Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphomaCarsten Kobe, Markus Dietlein, Jeremy Franklin, et al.
Hepatology (Baltimore, Md.)|April 5, 2012
Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventionsAndreas E Kremer, Remco van Dijk, Pamela Leckie, et al.
Leukemia|June 11, 2021
Gene expression-based outcome prediction in advanced stage classical Hodgkin lymphoma treated with BEACOPPRon D Jachimowicz, Wolfram Klapper, Gunther Glehr, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2012
Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trialsKarolin Behringer, Horst Mueller, Helen Goergen, et al.
British Journal of Haematology|August 28, 2015
Impact of centralized diagnostic review on quality of initial staging in Hodgkin lymphoma: experience of the German Hodgkin Study GroupPaul J Bröckelmann, Helen Goergen, Michael Fuchs, et al.
American Journal of Hematology|May 26, 2016
Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaborationChan Y Cheah, Paul J Bröckelmann, Dai Chihara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2010
Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trialHans Theodor Eich, Volker Diehl, Helen Görgen, et al.
Blood|December 18, 2010
Testing G-CSF responsiveness predicts the individual susceptibility to infection and consecutive treatment in recipients of high-dose chemotherapyChristian Straka, Michael Sandherr, Hans Salwender, et al.
Pageof 38